Cantor Fitzgerald lowered the firm’s price target on Gilead to $75 from $78 and keeps a Neutral rating on the shares. The firm, which made slight adjustments to all of its large-cap biotechnology models ahead of Q1 earnings season for the group, lowered its target for Gilead given slower expected HIV growth. The “usual seasonal headwinds that typically make this one of the weaker quarters for the industry,” the analyst added in the preview note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
- Unusually active option classes on open April 9th
- Fly Insider: Xilio, Aerovate among weekâs notable insider trades
- Nurix Therapeutics announces extension of collaboration with Gilead
- Gilead announces FDA approval for Vemlidy sNDA
